Phase III RELAY trial highlights the safety and efficacy of ramucirumab and erlotinib in elderly Japanese patients, indicating potential benefits for those with metastatic EGFR mutations.
Aim The global phase III RELAY trial demonstrated the efficacy of ramucirumab (RAM) plus erlotinib (ERL) in patients with untreated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We present safety and efficacy profiles of RAM+ERL in Japanese elderly (aged ≥ 75 years) patients in RELAY.
No takes yet. Share an insight, caveat, or question.
Nishino et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: